INNOVIVA, INC. Increase (Decrease) in Income Taxes Payable
INNOVIVA, INC. (INVA) reported Increase (Decrease) in Income Taxes Payable of $2.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-05
- INNOVIVA, INC. increase (decrease) in income taxes payable for the quarter ending 2026-06-30 was $1.59M.
- INNOVIVA, INC. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was $1.06M, a 55.47% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was $1.41M, a 96.35% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $728.00K, a 67.32% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in income taxes payable for fiscal 2025 was $4.06M, a 90.21% decline from fiscal 2024.
- INNOVIVA, INC. increase (decrease) in income taxes payable for fiscal 2024 was $41.48M, a 2304.41% increase from fiscal 2023.
- INNOVIVA, INC. increase (decrease) in income taxes payable for fiscal 2023 was $1.73M, a 82.79% decline from fiscal 2022.
- INNOVIVA, INC. increase (decrease) in income taxes payable for fiscal 2022 was $10.03M.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 6 month as first filed | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.65M 10-Q · filed 2026-08-05 | $4.06M derived: sum of 3 quarters · filed 2026-08-05 | $4.78M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-06 | $2.47M derived: sum of 2 quarters · filed 2026-05-06 | $3.20M derived: sum of 3 quarters · filed 2026-05-06 | $2.74M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.14M derived: sum of 2 quarters · filed 2026-02-25 | $1.68M derived: sum of 3 quarters · filed 2026-08-05 | $4.06M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $728.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $273.00K derived: sum of 2 quarters · filed 2026-08-05 | $2.65M 10-Q · filed 2025-11-05 | $41.35M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$455.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.92M 10-Q · filed 2026-08-05 | $40.63M derived: sum of 3 quarters · filed 2026-08-05 | $42.85M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.38M 10-Q · filed 2026-05-06 | $41.08M derived: sum of 2 quarters · filed 2026-05-06 | $43.31M derived: sum of 3 quarters · filed 2026-05-06 | $43.80M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $38.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $40.93M derived: sum of 2 quarters · filed 2026-02-25 | $41.43M derived: sum of 3 quarters · filed 2026-02-25 | $41.48M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.72M derived: sum of 2 quarters · filed 2025-11-05 | $2.77M 10-Q · filed 2025-11-05 | $4.35M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $494.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $543.00K 10-Q · filed 2025-08-06 | -$543.00K 10-Q · filed 2024-07-31 | $2.12M derived: sum of 3 quarters · filed 2026-02-25 | $2.17M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $49.00K 10-Q · filed 2025-05-07 | $1.63M derived: sum of 2 quarters · filed 2026-02-25 | $1.68M derived: sum of 3 quarters · filed 2026-02-25 | $1.73M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.63M derived: sum of 2 quarters · filed 2026-02-25 | $1.68M derived: sum of 3 quarters · filed 2026-02-25 | $1.73M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $99.00K derived: sum of 2 quarters · filed 2024-11-06 | $148.00K 10-Q · filed 2024-11-06 | -$23.63M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $99.00K 10-Q · filed 2024-07-31 | -$23.68M derived: sum of 3 quarters · filed 2025-02-26 | $10.13M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $49.00K 10-Q · filed 2024-05-08 | -$23.73M derived: sum of 2 quarters · filed 2025-02-26 | $10.07M derived: sum of 3 quarters · filed 2025-02-26 | $10.07M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | -$23.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $10.03M derived: sum of 2 quarters · filed 2025-02-26 | $10.03M derived: sum of 3 quarters · filed 2025-02-26 | $10.03M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $33.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $33.80M derived: sum of 2 quarters · filed 2023-11-01 | $33.80M 10-Q · filed 2023-11-01 | $33.80M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 10-K/A · filed 2024-03-05 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |